Efficacy of Different Immunological Approaches Targeting CD22 for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia: A Research Protocol

• DOI: 10.26685/urncst.340
• Publication Date: 2022-04-21T12:22:48Z
• Authors: Vitoria Olyntho; Cheryl (Jiayi) Xing; Erica Zeng
• Keywords: CD22; Refractory (planetary science)

Introduction: Monoclonal antibodies (mAbs) have emerged as a promising immune-oncological approach to target cancer cells. mAbs been seen outperform traditional drug treatments in treating severe cancers despite their low relative cytotoxicity due high selectivity. CD22 is expressed 60-90% of individuals with B-cell Acute Lymphoblastic Leukemia (B-ALL), and rapidly internalized when bound an antibody, making it effective point entry for cytotoxic agents. Epratuzumab anti-CD22 mAb, against B-ALL. Epratuzumab-SN-38 (Emab-SN-38) Inotuzumab ozogamicin (InO) are Antibody-Drug Conjugates (ADCs). Methods: Epratuzumab, Inotuzumab, Emab-SN38 will be evaluated vitro vivo. B lymphocytes collected from 30-35-year-old R/R ALL patient purified expanded. A cell culture assay evaluate the treatments. Cells engrafted into humanized mice. Mice assorted four treatment groups: saline (control), Emab-SN-38. Quantitative flow cytometric analysis used assess effectiveness. Complete Response determined ≅ zero human leukemic cells, Partial ≤5% Remission >5% cells or identifiable clinical signs. followed 6 months after last dose relapse survival rate. Results: It expected that all three result more significant results regarding tumour shrinkage rate growth than saline. The ADCs perform better unconjugated Epratuzumab. Relapse Adverse Event rates lowest Epratuzumab-SN-38. Discussion: comparison effectiveness these establish Emab-SN-38 potential option propel research other agents which could conjugation mAbs. Conclusion: combine chemotherapy specificity treat ALL. decreasing load given potent targeted cytotoxicity. less toxic but Inotuzumab. These inform on safer via CD22.